Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acnewell
- Development stage
- Unknown
- Lead developer
- Apeks Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Acnewell is a topical anti-acne medication containing 5% dapsone, developed by Apeks Pharma and manufactured by İlko İlaç. Dapsone is a sulfone compound that provides therapeutic benefits in acne vulgaris through both antibacterial and anti-inflammatory pathways. It acts as a competitive inhibitor of dihydropteroate synthase, thereby blocking bacterial folate synthesis, and also suppresses inflammatory responses by inhibiting myeloperoxidase activity and reducing neutrophil-mediated tissue damage. The product is formulated as a gel for topical application to the skin.
- Brand names
- Acnewell
- Other names
- Acnewell 5% Gel
02
Targets
DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on Acnewell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acnewell.